KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation

Sep 29, 2026

Uploaded by dbqoiu

April 2020 KDIGO Clinical Practice Guideline provides structured recommendations for evaluating and managing candidates for kidney transplantation. The guideline covers access to transplantation, age considerations, pediatric issues, and psychosocial assessment, with sections addressing adherence, tobacco use, surgical issues including obesity, and comorbidities such as diabetes, infections, malignancy, and major organ systems. It also includes cause of end-stage kidney disease, immunological assessment, and bone and mineral metabolism, supported by methods for guideline development, reference keys, and summarised recommendation statements.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages106

Reading Time4 h 27 min

AccessFree to download

Disclaimer

KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation

Summary of Recommendation Statements

Methods for Guideline Development

Section 1: Access to Transplantation

Section 2: Age

Section 3: Pediatric Issues

Section 4: Psychosocial Assessment

Section 5: Adherence

Section 6: Tobacco

Section 7: Surgical Issues including Obesity

Section 8: Diabetes

Section 9: Cause of End-Stage Kidney Disease (ESKD)

Section 10: Infections

Section 11: Malignancy

Section 12: Pulmonary Disease

Section 13: Cardiac Disease

Section 14: Peripheral Arterial Disease (PAD)

Section 15: Neurologic Disease

Section 16: Gastronintestinal and Liver Disease

Section 17: Hematologic Disorders

Section 18: Bone and Mineral Metabolism

Section 19: Immunological Assessment

References

April 2020 ■ Volume 104 ■ Number 4S Transplantation® KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation [www.transplantjournal.com](www.transplantjournal.com) April 2020 ■ Volume 104 ■ Number 4S Transplantation® Contents Disclaimer ...................................................................................................................................... S1 KDIGO Executive Committee ..................................................................................................... S2 Work Group Membership ............................................................................................................ S3 Preface ........................................................................................................................................... S4 Reference Keys............................................................................................................................. S6 KDIGO CKD Nomenclature ......................................................................................................... S7 Conversion Factors ...................................................................................................................... S8 Abbreviations and Acronyms...................................................................................................... S9 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.................................................................................... S11 Summary of Recommendation Statements ............................................................................. S11 Methods for Guideline Development ........................................................................................ S22 Section 1: Access to Transplantation ....................................................................................... S33 Section 2: Age ............................................................................................................................... S35 Section 3: Pediatric Issues ......................................................................................................... S36 Section 4: Psychosocial Assessment ....................................................................................... S37 Section 5: Adherence .................................................................................................................. S39 Section 6: Tobacco ....................................................................................................................... S41 Section 7: Surgical Issues including Obesity .......................................................................... S43 Section 8: Diabetes ...................................................................................................................... S46 Section 9: Cause of End-Stage Kidney Disease (ESKD) ....................................................... S47 Section 10: Infections.................................................................................................................. S55 Section 11: Malignancy ............................................................................................................... S63 Section 12: Pulmonary Disease ................................................................................................. S67 Section 13: Cardiac Disease ...................................................................................................... S68 Section 14: Peripheral Arterial Disease (PAD) ........................................................................ S72 Section 15: Neurologic Disease................................................................................................. S73 Section 16: Gastronintestinal and Liver Disease ...............................................

FAQs

What topics are included in the guideline for kidney transplant candidates?

It covers access to transplantation, age and pediatric issues, psychosocial assessment, adherence, tobacco, surgical issues including obesity, diabetes, infections, malignancy, pulmonary and cardiac disease, vascular disease, neurologic disease, gastrointestinal and liver disease, hematologic disorders, bone and mineral metabolism, and immunological assessment.

Where can readers find the guideline’s recommendation summaries and development methods?

The table of contents lists “Summary of Recommendation Statements” and “Methods for Guideline Development” within the main guideline section.

Does the guideline address immunological assessment and end-stage kidney disease causes?

Yes. It includes a dedicated section for “Cause of End-Stage Kidney Disease (ESKD)” and another for “Immunological Assessment,” alongside other clinical risk and assessment domains.

Sep 29, 2026

Uploaded by dbqoiu